In line with these observations, the analytical quantitative studies could be extended to chronic cholestatic diseases such as primary biliary cholangitis and primary sclerosing cholangitis, in order to evaluate the role of EpCAM and its relationship with ALP, fibrosis, and prognosis of the patients. This evidence concerns the gene EPCAM and sclerosing cholangitis.